Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation

In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first time, revealed which molecular mechanisms are involved in SOF effects on the impaired insulin response induced by HCV in hepatocyt...

Full description

Bibliographic Details
Authors: Rey, E., Ampuero Herrojo, Javier, Molina-Jiménez, F., García-García, Y., Muñoz Hernández, Rocío, Romero Gómez, Manuel, García-Monzón, C., Majano, P., González-Rodríguez, A.
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Universidad de Sevilla (US)
Repository:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/139181
Online Access:https://hdl.handle.net/11441/139181
https://doi.org/10.1002/ctm2.275
Access Level:Open access
Keyword:ALT
ApoB
Glycated hemoglobin
Description
Summary:In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first time, revealed which molecular mechanisms are involved in SOF effects on the impaired insulin response induced by HCV in hepatocytes.

Similar Items